HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

670.135

+9.6471.46%

Number of Gainers:17

Number of Losers:13

Number of Flat:4

PE:- -

High:678.126

Open:660.587

Low:657.123

Close:660.489

Volume:153.72M

Turnover:4.63B

Market Cap:429.95B

Float Cap:380.25B

Loading ...

Comprehensive Analysis of Biopharmaceutical Industry Operations: Innovative Drug Companies Lead R&D, Significant Divergence in Scale and Profitability

SM17 Phase 2 Trial for Atopic Dermatitis Administers First Dose in China

ZYLOXTB (02190) Repurchases 48,000 Shares for HK$1.16 Million on April 1

SinoMab doses first patient in China Phase 2 trial of SM17 for atopic dermatitis

China Galaxy Securities: Strategic Positioning Upgrade Drives High-Quality Development in Pharmaceuticals, Recommends Focus on Innovative Drugs and Medical AI

Innovative Drug Sector Sees Resurgence After Half-Year Hiatus, Leaders Enter Intensive Harvest Phase

SIHUAN PHARM and BIOCYTOGEN-B Forge Strategic Alliance to Accelerate Innovative Drug Development in Weight Loss and Other Areas Using AI-Powered Human Antibody Platform

Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288

Hong Kong Market Wrap: Hang Seng Jumps 2.04%, Tech Index Up 2.29%

Chinese Stocks Rebound as Healthcare Shares Surge on Four Key Catalysts

CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint

MT Newswires Live

ZhongOu Healthcare Fund's Annual Report Released: Core Holdings Remain Concentrated on Innovative Drug Industry Chain

OCUMENSION-B Shares Surge Over 16% Afternoon Following First Patient Enrollment in Phase III Dry Eye Treatment Trial

PEIJIA-B Shares Surge Over 7% in Afternoon Trading as Institutions Highlight TAVR Segment Benefits

E Fund Innovation Pharmaceuticals ETF: A Strategic Window Amid Policy Support and Industry Synergy

National Healthcare Security Administration Sets Red Lines for Fraudulent Insurance Claims: Policyholders Face Penalties for Specific Offenses

Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%

MT Newswires Live

TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement

CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround

Innovative Drugs Lead the Charge as Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 6% on Heavy Volume

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":670.1354,"timestamp":1775117299351,"preClose":660.4887,"halted":0,"volume":153717417,"delay":0,"changeRate":0.014605,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed The day following Ching Ming Festival","change":9.646667,"latestTime":"04-02 16:00:00","open":660.58655,"high":678.1257,"low":657.12256,"amount":4633342498,"amplitude":0.031799,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"pbRate":5.274197,"peRate":-86.845688,"turnoverRate":0.005552,"increases":17,"decrements":14,"flats":2,"marketCap":429946652416,"floatMarketCap":380251567184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":678.1257,"amplitude":0.031799,"preClose":660.4887,"low":657.12256,"pbRate":"5.274197","latestPrice":670.1354,"volume":153717417,"delay":0,"open":660.58655,"prevYearClose":556.26263,"prevWeekClose":670.135,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":579.36,"twentyDayClose":522.155,"sixtyDayClose":580.971,"secType":"PLATE","market":"HK","turnoverRate":0.005552,"peRate":-86.845688,"marketCap":429946652416,"floatMarketCap":380251567184,"timestamp":1775117299351,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":13,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1139731446","title":"Comprehensive Analysis of Biopharmaceutical Industry Operations: Innovative Drug Companies Lead R&D, Significant Divergence in Scale and Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1139731446","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139731446?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:01","pubTimestamp":1775037689,"startTime":"0","endTime":"0","summary":"Recent disclosures of 2025 annual financial reports by listed companies reveal operational data from 11 biopharmaceutical firms. This analysis provides an in-depth examination of full-dimensional...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116443811","title":"SM17 Phase 2 Trial for Atopic Dermatitis Administers First Dose in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1116443811","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116443811?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:54","pubTimestamp":1775037289,"startTime":"0","endTime":"0","summary":"SINOMAB BIO-B (03681) has announced that on March 31, 2026, the first patient in its Phase 2 clinical trial for SM17 in treating atopic dermatitis was successfully dosed in China. This Phase 2 study...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160762767","title":"ZYLOXTB (02190) Repurchases 48,000 Shares for HK$1.16 Million on April 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1160762767","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160762767?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:48","pubTimestamp":1775036895,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) announced that on April 1, the company repurchased 48,000 of its shares for a total of HK$1.16 million. The price per share ranged from HK$23.78 to HK$24.14.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","02190","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591953","title":"SinoMab doses first patient in China Phase 2 trial of SM17 for atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591953","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624591953?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:47","pubTimestamp":1775036857,"startTime":"0","endTime":"0","summary":"SinoMab BioScience dosed first patient on March 31, 2026 in a Phase 2 China trial of SM17 for moderate-to-severe atopic dermatitis.Study will test subcutaneous SM17 across multiple dose groups versus placebo in about 210 patients, with readouts planned through Week 24.Program follows previously presented positive Phase 1b topline results in atopic dermatitis, supporting continued development for both itch relief and skin improvement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6dPlN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121135406","title":"China Galaxy Securities: Strategic Positioning Upgrade Drives High-Quality Development in Pharmaceuticals, Recommends Focus on Innovative Drugs and Medical AI","url":"https://stock-news.laohu8.com/highlight/detail?id=1121135406","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121135406?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:31","pubTimestamp":1775035868,"startTime":"0","endTime":"0","summary":"A research report from China Galaxy Securities indicates that the 15th Five-Year Plan is expected to continue driving the development of the biopharmaceutical industry. The firm is optimistic about...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1147","BK0276","161027","BK1515","BK1564","601881","BK1574","06881","159992","150261","06978","159938","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197801243","title":"Innovative Drug Sector Sees Resurgence After Half-Year Hiatus, Leaders Enter Intensive Harvest Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1197801243","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197801243?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:18","pubTimestamp":1775035105,"startTime":"0","endTime":"0","summary":"On April 1, the innovative drug concept surged collectively, with Guang Sheng Tang hitting the 20% daily limit up. BeiDa Pharmaceutical, Baili Tianheng, and Asymchem Laboratories also rose by the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143375483","title":"SIHUAN PHARM and BIOCYTOGEN-B Forge Strategic Alliance to Accelerate Innovative Drug Development in Weight Loss and Other Areas Using AI-Powered Human Antibody Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1143375483","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143375483?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:12","pubTimestamp":1775034756,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) has announced that the Group has officially entered into a strategic collaboration agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 688796.SH;...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159992","02315","AGIX","AIPO","BK1191","688796","CHAT","BK0216","00460","BK1574","BK1600","06978","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194246479","title":"Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288","url":"https://stock-news.laohu8.com/highlight/detail?id=1194246479","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194246479?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:50","pubTimestamp":1775033435,"startTime":"0","endTime":"0","summary":"Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK1583","BK4080","LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","ADC","BK1574","09995","688331","BK1161","LU1969619763.USD","LU2328871848.SGD","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104857119","title":"Hong Kong Market Wrap: Hang Seng Jumps 2.04%, Tech Index Up 2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104857119","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104857119?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:23","pubTimestamp":1775031792,"startTime":"0","endTime":"0","summary":"Hong Kong's three major stock indices closed higher on April 1. The Hang Seng Index rose 2.04% to 25,294.03 points, while the Hang Seng Tech Index gained 2.29% and the Hang Seng China Enterprises...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9a2e3148d7a49653b8d344300ab72163","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1618","SG9999001051.SGD","BK4504","BK1608","HSTECH","LU2097828805.USD","BK1587","BK1104","BK1161","LU2097828714.EUR","BK4085","LU2097828474.EUR","HSI","BK1574","SG9999006597.SGD","HSImain","BK1615","MCHmain","BK4077","BK4510","SG9999001093.SGD","BK1575","BK4566","IE0034224299.USD","LU2097828631.EUR","BK4585","HHImain","SG9999001069.SGD","513600","02833","BK4554","BK1588","BK4526","HTImain","BK4588","BK1095","BK4548","BK4509","BK4503","BK4513","BK4563","LU2097828557.USD","SG9999003461.SGD","BK4505","BK4531","BK4577"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139788278","title":"Chinese Stocks Rebound as Healthcare Shares Surge on Four Key Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1139788278","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139788278?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:03","pubTimestamp":1775030612,"startTime":"0","endTime":"0","summary":"On the first trading day of April, major Asia-Pacific stock markets rallied significantly, with A-shares joining the upswing. By market close, the Shanghai Composite Index had risen 1.46%, the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399300","BK1574","BK1515","159938","09939","BK1161","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624936385","title":"CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2624936385","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624936385?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:00","pubTimestamp":1775030416,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said the Anbenitamab Injection has met the primary endpoint in a phase III study and demonstrated improved total pathological complete response, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm were up over 6% in Wednesday afternoon trading.The Anbenitamab Injection is co-developed by CSPC Pharmaceutical's unit Shanghai JMT-BIO Technology and Alphamab Oncology's  subsidiary Jiangsu Alphamab Oncology.The trial is studying the drug in combination with Docetaxel for Injection for the treatment of HER2-positive early or locally advanced breast cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226288170.HKD","LU1807302812.USD","HK0000165453.HKD","LU1226287529.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","BK1521","IE0008369823.USD","IE00B031HY20.USD","BK1191","BK1161","LU0326950275.SGD","LU1152091168.USD","LU2039709279.SGD","LU1813983027.USD","LU1951186391.HKD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","01093","LU0501845795.SGD","IE00BZ08YR35.GBP","LU0067412154.USD","LU1960683339.HKD","LU1993786604.SGD","SG9999004220.SGD","BK1574","09966","LU0314109678.HKD","LU1226287875.USD","BK1515","IE0008368742.USD","LU0140636845.USD","LU0315179316.USD","IE00BZ08YT58.USD","LU0072913022.USD","LU1226287792.SGD","LU1328277881.USD","LU1226288253.USD","LU0880133367.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179267528","title":"ZhongOu Healthcare Fund's Annual Report Released: Core Holdings Remain Concentrated on Innovative Drug Industry Chain","url":"https://stock-news.laohu8.com/highlight/detail?id=1179267528","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179267528?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:42","pubTimestamp":1775025766,"startTime":"0","endTime":"0","summary":"The annual report for 2025 of the fund managed by Ge Lan of ZhongOu Fund was released on March 31. Taking the ZhongOu Healthcare Fund, which represents her largest management scale, as an example,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","VHT","BK4550","BK4581","BK4588","159992","BK1161","159760","BK1574","IXJ","XBI","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113085837","title":"OCUMENSION-B Shares Surge Over 16% Afternoon Following First Patient Enrollment in Phase III Dry Eye Treatment Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1113085837","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113085837?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:30","pubTimestamp":1775025022,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) saw its shares rise more than 16% in afternoon trading. As of the time of writing, the stock was up 15.33%, trading at HK$8.5 with a turnover of HK$26.0687 million. The movement...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK4134","VXUS","BK4588","III","BK4585","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115085783","title":"PEIJIA-B Shares Surge Over 7% in Afternoon Trading as Institutions Highlight TAVR Segment Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=1115085783","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115085783?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:26","pubTimestamp":1775024760,"startTime":"0","endTime":"0","summary":"PEIJIA-B (09996) rose more than 7% in afternoon trading. At the time of writing, the stock was up 6.87% to HK$6.07, with a turnover of HK$6.103 million. The company previously released its annual...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","09996","BK1574","BK4588","BK1100","BK1583","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108173549","title":"E Fund Innovation Pharmaceuticals ETF: A Strategic Window Amid Policy Support and Industry Synergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1108173549","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108173549?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:22","pubTimestamp":1775024551,"startTime":"0","endTime":"0","summary":"The innovation pharmaceuticals sector remained active during the afternoon session, emerging as one of the standout performers in a volatile market. By 13:20, the concept stocks showed repeated...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173800982","title":"National Healthcare Security Administration Sets Red Lines for Fraudulent Insurance Claims: Policyholders Face Penalties for Specific Offenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1173800982","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173800982?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:30","pubTimestamp":1775021452,"startTime":"0","endTime":"0","summary":"Effective today (1st), the \"Detailed Implementation Rules for the Regulations on the Supervision and Management of Healthcare Security Fund Usage\" have come into force. Key fraudulent activities such...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656901","title":"Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656901","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624656901?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:02","pubTimestamp":1775019764,"startTime":"0","endTime":"0","summary":"Ascletis Pharma's  loss attributable to equity shareholders came in at 359.9 million yuan for 2025, widening 20% from 300.9 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm were up over 5% in Wednesday's midday trade.Loss per share came in at 0.3701 yuan, compared with 0.3005 yuan in the prior year.Total income rose 5.2% to 127.4 million yuan from 121.1 million yuan in 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01672","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153741167","title":"TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1153741167","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153741167?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:02","pubTimestamp":1775016153,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) saw its shares rise more than 7%. As of the time of writing, the stock was up 7.07%, trading at HKD 10.9 with a turnover of HKD 30.54 million. On March 31, TYK MEDICINES-B...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","159938","06978","09939","159992","02410","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164679653","title":"CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1164679653","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164679653?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:00","pubTimestamp":1775016017,"startTime":"0","endTime":"0","summary":"CANSINOBIO (06185) saw its shares rise by nearly 10% in pre-midday trading. As of the time of writing, the stock was up 9.49%, trading at HKD 34.16, with a turnover of HKD 28.35 million. The movement...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4588","BK4585","BK1515","VXUS","06185","159646","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156487336","title":"Innovative Drugs Lead the Charge as Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 6% on Heavy Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=1156487336","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156487336?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:40","pubTimestamp":1775014849,"startTime":"0","endTime":"0","summary":"On April 1, innovative drug stocks led the Hong Kong market with strong gains. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses exclusively on innovative drug R&D...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","159891","159137","520880","BK4588","159992","BK1161","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":4,"totalSize":374,"code":"91000000","status":"200"}]}}